There are limited reports demonstrating clinical feasibility of detecting T790M from cfDNA in NSCLC patients who failed prior EGFR-TKI treatment compared to those reporting about major activating mutations like Del 19 or L858R [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.